Recruitment

Recruitment Status
Active, not recruiting

Inclusion Criteria

Head and neck cancer stage III and IV
Ovarian cancer, stage III and IV
Melanoma, stage III and IV
...
Head and neck cancer stage III and IV
Ovarian cancer, stage III and IV
Melanoma, stage III and IV
Acute myeloid leukemia
Small cell lung cancer, limited stage and extensive stage
Breast cancer, stage IV, if triple negative ER/PR/H2N negative or on systemic chemotherapy
Renal cell carcinoma, stage IV
Rectal cancer stage II, III, IV
Patient must have ongoing oncologic needs and plan to receive all care at the study institution and not already be in hospice or home-care
Esophageal cancer stage III and IV
Colon cancer stage III and IV
Any patient with recurrent or progressive cancer
Gastric cancer stage III and IV
Pancreatic cancer stage II, III, IV
Bladder carcinoma, stage IV
Patients must have the ability to understand and willingness to sign a written informed consent document
Sarcoma, stage IV
Glioblastoma multiforme (brain) -- no stage
Castration-resistant prostate cancer
High grade myelodysplastic syndrome (MDS)
Non-small cell lung cancer stage IIIA, IIIB, IV

Exclusion Criteria

Patients must have capacity to consent
Pregnant patients are excluded
Patients must have capacity to consent
Pregnant patients are excluded

Summary

Conditions
  • Extensive Stage Small Cell Lung Carcinoma
  • Acute Myeloid Leukemia
  • Brain Glioblastoma
  • Estrogen Receptor Negative
  • Stage IIB Rectal Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IV Bone Sarcoma
  • Stage IVA Bone Sarcoma
  • Head and Neck Carcinoma
  • Stage IIIB Ovarian Cancer
  • Stage IV Gastric Cancer
  • Stage IVB Rectal Cancer
  • Stage IIIA Colon Cancer
  • Stage IIIB Rectal Cancer
  • Stage IIIC Rectal Cancer
  • Recurrent Carcinoma
  • Stage IV Skin Melanoma
  • Stage IIIC Gastric Cancer
  • Stage IV Rectal Cancer
  • Stage IV Colon Cancer
  • Stage IIB Pancreatic Cancer
  • HER2/Neu Negative
  • Stage IIIB Skin Melanoma
  • Stage III Esophageal Cancer
  • Stage IIIC Esophageal Cancer
  • Stage IV Pancreatic Cancer
  • Stage IV Bladder Cancer
  • Stage IIA Pancreatic Cancer
  • Stage III Colon Cancer
  • Stage IVB Bone Sarcoma
  • Stage IV Non-small Cell Lung Cancer
  • Stage IVA Colon Cancer
  • Stage IIIA Esophageal Cancer
  • Stage IIIA Rectal Cancer
  • Stage IIIB Colon Cancer
  • Stage IIIB Gastric Cancer
  • Stage IVA Rectal Cancer
  • Stage IIIB Esophageal Cancer
  • Stage IIIA Skin Melanoma
  • Stage III Gastric Cancer
  • Stage III Ovarian Cancer
  • Stage IV Breast Cancer
  • Stage III Skin Melanoma
  • Triple-Negative Breast Carcinoma
  • Stage IV Renal Cell Cancer
  • Hormone-Resistant Prostate Cancer
  • Limited Stage Small Cell Lung Carcinoma
  • Stage IIC Rectal Cancer
  • Stage IV Soft Tissue Sarcoma
  • Stage IV Ovarian Cancer
  • Stage II Pancreatic Cancer
  • Stage IV Esophageal Cancer
  • Stage III Non-Small Cell Lung Cancer
  • Stage IIIC Colon Cancer
  • Myelodysplastic Syndrome
  • Progesterone Receptor Negative
  • Progressive Disease
  • Stage IIIA Gastric Cancer
  • Stage III Rectal Cancer
  • Stage IIIC Skin Melanoma
  • Stage II Rectal Cancer
  • Stage IIA Rectal Cancer
  • Stage IIIB Non Small Cell Lung Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IVB Colon Cancer
  • Stage III Pancreatic Cancer
  • Stage IIIA Non-Small Cell Lung Cancer
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Health Services Research

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

PRIMARY OBJECTIVES: I. To reduce acute care utilization by 2-5% for advanced cancer patients by training and deploying health care coaches who help patients and families discuss care goals, virtual modalities, engage in shared-decision-making, and participate in educational activities. SECONDARY OBJ...

PRIMARY OBJECTIVES: I. To reduce acute care utilization by 2-5% for advanced cancer patients by training and deploying health care coaches who help patients and families discuss care goals, virtual modalities, engage in shared-decision-making, and participate in educational activities. SECONDARY OBJECTIVES: I. To improve patients' experience of their care. II. Improve patient understanding of advanced care planning. III. To improve the receipt of goal concordant care. IV. To reduce total healthcare costs. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive usual care. ARM B: Patients undergo health care coach support with a baseline introduction (either telephonic or in-person) of the program followed by a visit (telephonic or in-person) with the health care coach after the first oncology appointment to discuss goals of care. The health care coach will contact patient based on patients' ongoing needs (weekly to monthly) and will conduct symptom assessments based on patients' treatment plans and symptoms. After completion of study, patients are followed up for 6 months.

Inclusion Criteria

Head and neck cancer stage III and IV
Ovarian cancer, stage III and IV
Melanoma, stage III and IV
...
Head and neck cancer stage III and IV
Ovarian cancer, stage III and IV
Melanoma, stage III and IV
Acute myeloid leukemia
Small cell lung cancer, limited stage and extensive stage
Breast cancer, stage IV, if triple negative ER/PR/H2N negative or on systemic chemotherapy
Renal cell carcinoma, stage IV
Rectal cancer stage II, III, IV
Patient must have ongoing oncologic needs and plan to receive all care at the study institution and not already be in hospice or home-care
Esophageal cancer stage III and IV
Colon cancer stage III and IV
Any patient with recurrent or progressive cancer
Gastric cancer stage III and IV
Pancreatic cancer stage II, III, IV
Bladder carcinoma, stage IV
Patients must have the ability to understand and willingness to sign a written informed consent document
Sarcoma, stage IV
Glioblastoma multiforme (brain) -- no stage
Castration-resistant prostate cancer
High grade myelodysplastic syndrome (MDS)
Non-small cell lung cancer stage IIIA, IIIB, IV

Exclusion Criteria

Patients must have capacity to consent
Pregnant patients are excluded
Patients must have capacity to consent
Pregnant patients are excluded

Locations

Fullerton, California, 29835
Fullerton, California, 29835

Tracking Information

NCT #
NCT03154190
Collaborators
Not Provided
Investigators
  • Principal Investigator: Manali Patel Stanford University
  • Manali Patel Stanford University